Potential role of maternal serum microRNAs as a biomarker for fetal congenital heart defects

Medical Hypotheses

Volumn 76, Issue 3, 2011, Pages 424-426

  Yu, Zhangbin ^a   Han, Shuping ^a   Hu, Ping ^a   Zhu, Chun ^a   Wang, Xuejie ^a   Qian, Lingmei ^b   Guo, Xirong ^a  

^a WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; MICRORNA; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; BLOOD; CONGENITAL HEART MALFORMATION; DIAGNOSTIC ACCURACY; DISEASE MARKER; ECHOCARDIOGRAPHY; FALSE POSITIVE RESULT; FETUS CONGENITAL HEART MALFORMATION; FETUS ECHOGRAPHY; FETUS MORTALITY; GENE EXPRESSION; HEART DEVELOPMENT; HUMAN; MATERNAL SERUM; NATIONAL HEALTH SERVICE; NEWBORN MORBIDITY; NUCHAL TRANSLUCENCY MEASUREMENT; OPERATOR; PARENT COUNSELING; PRENATAL SCREENING; PSYCHOLOGICAL WELL BEING; SKILL; WORK EXPERIENCE;

BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; FETUS; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; MICRORNAS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A;

EID: 79751528167     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.11.010     Document Type: Article

References (32)

1. Capozzi G., Caputo S., Pizzuti R., Martina L., Santoro M., Santoro G., et al. Congenital heart disease in live-born children: incidence, distribution, and yearly changes in the Campania Region. J Cardiovasc Med (Hagerstown) 2008, 9(4):368-374.
2. Jone P.N., Schowengerdt K.O. Prenatal diagnosis of congenital heart disease. Pediatr Clin North Am 2009, 56(3):709-715.
3. Trojnarska O., Grajek S., Katarzynski S., Kramer L. Predictors mortality of in adult patients with congenital heart disease. Cardiol J 2009, 16(4):341-347.
4. Dearani J.A., Mavroudis C., Quintessenza J., Deal B.J., Backer C.L., Fitzgerald P., et al. Surgical advances in the treatment of adults with congenital heart disease. Curr Opin Pediatr 2009, 21(5):565-572.
5. Fuchs I.B., Muller H., Abdul-Khaliq H., Harder T., Dudenhausen J.W., Henrich W. Immediate and long-term outcomes in children with prenatal diagnosis of selected isolated congenital heart defects. Ultrasound Obstet Gynecol 2007, 29(1):38-43.
6. Paladini D., Russo M., Teodoro A., Pacileo G., Capozzi G., Martinelli P., et al. Prenatal diagnosis of congenital heart disease in the Naples area during the years 1994-1999 - the experience of a joint fetal-pediatric cardiology unit. Prenat Diagn 2002, 22(7):545-552.
7. Rasiah S.V., Publicover M., Ewer A.K., Khan K.S., Kilby M.D., Zamora J. A systematic review of the accuracy of first-trimester ultrasound examination for detecting major congenital heart disease. Ultrasound Obstet Gynecol 2006, 28(1):110-116.
8. Tegnander E., Eik-Nes S.H. The examiner's ultrasound experience has a significant impact on the detection rate of congenital heart defects at the second-trimester fetal examination. Ultrasound Obstet Gynecol 2006, 28(1):8-14.
9. Carvalho J.S., Mavrides E., Shinebourne E.A., Campbell S., Thilaganathan B. Improving the effectiveness of routine prenatal screening for major congenital heart defects. Heart 2002, 88(4):387-391.
10. Friedberg M.K., Silverman N.H., Moon-Grady A.J., Tong E., Nourse J., Sorenson B., et al. Prenatal detection of congenital heart disease. J Pediatr 2009, 155(1):26-31.
11. Khoshnood B., De Vigan C., Vodovar V., Goujard J., Lhomme A., Bonnet D., et al. Trends in prenatal diagnosis, pregnancy termination, and perinatal mortality of newborns with congenital heart disease in France, 1983-2000: a population-based evaluation. Pediatrics 2005, 115(1):95-101.
12. Bruns R.F., Moron A.F., Murta C.G., Goncalves L.F., Zamith M.M. The role of nuchal translucency in the screening for congenital heart defects. Arq Bras Cardiol 2006, 87(3):307-314.
13. Wald N.J., Morris J.K., Walker K., Simpson J.M. Prenatal screening for serious congenital heart defects using nuchal translucency: a meta-analysis. Prenat Diagn 2008, 28(12):1094-1104.
14. Lemon B.S. Nuchal translucency for prenatal screening? What nurses need to know about this tool. AWHONN Lifelines 2004, 8(6):520-526.
15. Jelliffe-Pawlowski L.L., Walton-Haynes L., Currier R.J. Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results. Am J Med Genet A 2008, 146A(19):2455-2467.
16. Jelliffe-Pawlowski L.L., Walton-Haynes L., Currier R.J. Identification of second trimester screen positive pregnancies at increased risk for congenital heart defects. Prenat Diagn 2009, 29(6):570-577.
17. Zhang L., Li H., Benedek D., Li X., Ursano R. A strategy for the development of biomarker tests for PTSD. Med Hypotheses 2009, 73(3):404-409.
18. Arcelli D., Farina A., Cappuzzello C., Bresin A., De Sanctis P., Perolo A., et al. Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening. Prenat Diagn 2010, 30(3):229-234.
19. Thum T., Catalucci D., Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 2008, 79(4):562-570.
20. Chim S.S., Shing T.K., Hung E.C., Leung T.Y., Lau T.K., Chiu R.W., et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008, 54(3):482-490.
21. Benfey P.N. Molecular biology: microRNA is here to stay. Nature 2003, 425(6955):244-245.
22. Wang Y., Liang Y., Lu Q. MicroRNA epigenetic alterations: predicting biomarkers and therapeutic targets in human diseases. Clin Genet 2008, 74(4):307-315.
23. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18(10):997-1006.
24. Gilad S., Meiri E., Yogev Y., Benjamin S., Lebanony D., Yerushalmi N., et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3(9):e3148.
25. Cortez M.A., Calin G.A. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009, 9(6):703-711.
26. Chin L.J., Slack F.J. A truth serum for cancer - microRNAs have major potential as cancer biomarkers. Cell Res 2008, 18(10):983-984.
27. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105(30):10513-10518.
28. Jung M., Mollenkopf H.J., Grimm C., Wagner I., Albrecht M., Waller T., et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009, 13(9B):3918-3928.
29. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009, 106(11):4402-4407.
30. Liu D.Z., Tian Y., Ander B.P., Xu H., Stamova B.S., Zhan X., et al. Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J Cereb Blood Flow Metab 2010, 30(1):92-101.
31. Catalucci D., Latronico M.V., Condorelli G. MicroRNAs control gene expression: importance for cardiac development and pathophysiology. Ann NY Acad Sci 2008, 1123:20-29.
32. Liang Y., Ridzon D., Wong L., Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007, 8:166.